At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 315 enrolled
Drug / intervention
Fluticasone furoate nasal spray +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of Once-Daily Intranasal Administration of Fluticasone Furoate Nasal Spray 110mcg in Adult and Adolescent Subjects 12 Years of Age and Older With Perennial Allergic Rhinitis (PAR)
In Brief
A Phase 4 clinical trial evaluating Fluticasone furoate nasal spray and Placebo for Rhinitis, Allergic, Perennial. Completed, enrolled 315 participants across 37 sites in 7 countries.
Detailed Summary
The purpose of this study is to compare the effects (effectiveness and safety) of an intranasal corticosteroid (fluticasone furoate nasal spray \[FFNS\]), with a placebo nasal spray for the treatment of perennial (year-round) allergic rhinitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRhinitis, Allergic, Perennial
CountriesCanada, Estonia, Germany, Hungary, Russia, Slovakia, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedFeb 2008
Primary CompletionJun 2008
TodayJul 2026
First PostedFeb 7, 2008
Enrollment StartJan 1, 2008
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 18.4 years ago
Interventions
Fluticasone furoate nasal spraydrug
Fluticasone furoate nasal spray
Placebodrug
Placebo